Amphastar Pharmaceuticals's Q1 Earnings Call: Our Top 5 Analyst Questions [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
non-GAAP earnings per share came in above expectations. Management attributed the revenue outcome to ongoing competition in critical care products such as Glucagon and Epinephrine, with Senior Vice President Dan Dischner noting, “demand for these products softened due to increased competition.” The company's diversified product portfolio, particularly the strong performance of Primatene MIST, helped to counterbalance these competitive pressures and maintain operational resilience in a dynamic market environment. Is now the time to buy AMPH? Find out in our full research report (it's free). Revenue: $170.5 million vs analyst estimates of $173.9 million (flat year on year, 2% miss) Adjusted EPS: $0.74 vs analyst estimates of $0.69 (7.6% beat) Adjusted EBITDA: $59.3 million vs analyst estimates of $52.85 million (34.8% margin, 12.2% beat) Operating Margin: 21.9%, down from 27.9% in the same quarter last year Market Capitalization: $1.09 billion While we enjoy listening to t
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Amphastar Director Sells 16,679 Shares for $441,800 [Yahoo! Finance]Yahoo! Finance
- Will FDA Approval of an In-House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative? [Yahoo! Finance]Yahoo! Finance
- Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile [Seeking Alpha]Seeking Alpha
- 2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by analysts at Barclays PLC to a "hold" rating.MarketBeat
AMPH
Earnings
- 11/6/25 - Beat
AMPH
Sec Filings
- 12/18/25 - Form 4
- 12/15/25 - Form 4
- 12/11/25 - Form 144
- AMPH's page on the SEC website